ReviewAntibiotics (Basel, Switzerland)2021
The Emergence of Multidrug-Resistant
Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 42 citations in OpenAlex.
- Efficacy of fourteen-day once-daily vonoprazan-based quadruple therapy for Helicobacter pylori in high clarithromycin-resistance regions (ONCE-VONO Trial).Scientific reports · 2025Trial
- Adjunctive Synbiotic Therapy forLife (Basel, Switzerland) · 2026Review
- Transcriptomic and Molecular Insights into the Response of Multidrug-Resistant Helicobacter pylori to Human Neutrophil Peptide 1 (HNP-1).Probiotics and antimicrobial proteins · 2026Article
- Rationally Engineered D-Amino Acid Peptide DT7-3 Combats Multidrug-ResistantMicroorganisms · 2026Article
- Burden, clinical impact, and primary antimicrobial resistance profiles of Helicobacter pylori infections in Cameroon: A systematic review and meta-analysis.PLOS global public health · 2026Article
- Designing and immuno-informatics evaluation of a multi-epitope vaccine targeting lipoprotein A-4'-phosphatase (LpxF) forFrontiers in bioinformatics · 2026Article
- Comparative Efficacy of Triple Versus Quadruple Therapy for the Eradication ofJGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Development of a multi-epitope vaccine against Helicobacter pylori using a novel saRNA technology through an immunoinformatics approach.Scientific reports · 2025Article
- Anti-Molecules (Basel, Switzerland) · 2025Article
- Establishment of an intragastric surgical model using C57BL/6 mice to study the vaccine efficacy of OMV-based immunogens against Helicobacter pylori.Biology open · 2025Article
- Repurposing FDA-Approved Agents to Develop a PrototypePharmaceuticals (Basel, Switzerland) · 2025Article
- Opportunities forMicroorganisms · 2024Review
- Article
- Article
- Comparison of the management of Helicobacter pylori infection between the older and younger European populations.Scientific reports · 2023Article
- OptimizingGut and liver · 2023Review
- Targeted delivery of a short antimicrobial peptide (CM11) against Helicobacter pylori gastric infection using concanavalin A-coated chitosan nanoparticles.Journal of materials science. Materials in medicine · 2023Article
- Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents.Archives of microbiology · 2023Review
- The Potential of Alternative Therapies and Vaccine Candidates againstPharmaceuticals (Basel, Switzerland) · 2023Review
- Drug Resistance Patterns of Commonly Used Antibiotics for the Treatment ofTropical medicine and infectious disease · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
The emergence of multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.